Introduction {#s1}
============

Dystrophinopathies are the most frequent neuromuscular disorder. They are caused by mutations in the *DMD* gene, one of the largest genes found in humans [@pone.0059916-Hoffman1], [@pone.0059916-Koenig1]. *DMD* encodes for dystrophin, a key player in the stabilization of the sarcolemma during muscle contraction [@pone.0059916-Ervasti1]. Clinical phenotypes include severe Duchenne muscular dystrophy (DMD), milder Becker muscular dystrophy (BMD), intermediate muscular dystrophy (IMD) and pure cardiac X-linked dilated cardiomyopathy (XLCM). DMD is characterized by early-onset, rapidly progressive muscular weakness, leading to wheel-chair dependency before age 13 and death during the third decade. BMD is clinically heterogeneous but presents a later onset and slower progression [@pone.0059916-Beggs1].

Clinical severity is determined by the maintenance of the open reading-frame, allowing the expression of semi-functional dystrophin with preserved N-term and C-term protein-binding domains [@pone.0059916-Monaco1]. Some parts of the central rod-domain can be truncated with minimal impact on protein function [@pone.0059916-England1]. Frameshift and nonsense mutations cause absence of dystrophin expression and a DMD phenotype. In-frame mutations lead to abnormal or reduced dystrophin in muscle causing BMD. On this particular feature is based the promising molecular therapy of antisense oligonucleotide (AON)--mediated exon-skipping. Targeting splicing motifs of the pre-mRNA can induce the exclusion of selected exons and restoration of an open reading-frame, theoretically allowing the conversion of DMD to the BMD phenotype [@pone.0059916-vanDeutekom1]--[@pone.0059916-Popplewell1].

Until recent years, molecular diagnosis was mainly limited to detection of exonic deletions and duplications accounting for 65--70% of all disease-causing mutations [@pone.0059916-AartsmaRus2], [@pone.0059916-TufferyGiraud1]. Detection of the remaining 25--30% single point mutations or small rearrangements have historically been challenging due to the large size of *DMD* gene. Development of high-throughput screening methodologies has allowed routine diagnosis of these mutations [@pone.0059916-Flanigan1]. However, the mutation impact on pre-mRNA splicing and protein expression is often unknown.

Exceptions to the reading-frame rule are found in approximately 9% of patients and the production of alternatively spliced transcripts is considered a key modifier of the clinical severity [@pone.0059916-AartsmaRus2]. Skipping of the mutated exon has been reported in several nonsense BMD-associated mutations, suggesting a model based on disruption/creation of splicing regulatory elements (SRE) [@pone.0059916-Shiga1]--[@pone.0059916-Disset1]. However, some findings suggest that SRE alteration is not the only factor determining exon-skipping [@pone.0059916-Tran1]--[@pone.0059916-Cartegni1]. Recently, Flanigan and co-workers postulated that exon-skipping occurs in a subset of weakly defined *DMD* exons [@pone.0059916-Flanigan2]. It has also been found that splice site mutations can lead to exon-skipping or activation of cryptic splice sites [@pone.0059916-TufferyGiraud3]--[@pone.0059916-Takeshima1]. Nevertheless, the main factors determining the final splicing pathway are still unclear.

The precise definition of *DMD* point mutations and their consequences help to improve our understanding of the molecular pathology in dystrophinopathies. Due to its particular features and size, *DMD* is a suitable model gene for the study of the in vivo effects of DNA variants on mRNA and the elements involved in the regulation of the splicing process. Point mutations also provide valuable information regarding critical protein domains for dystrophin function. Herein we report our results concerning the clinical phenotype, dystrophin expression and *DMD* molecular analysis in 105 dystrophinopathy patients, presenting 98 different point mutations. Muscle mRNA analysis performed in most patients, identified 27 mutations causing aberrant pre-mRNA splicing. The mechanisms involved in the development of splicing defects included abrogation of natural splice sites, creation of new splice sites, alteration of SREs and pseudoexon activation. Bioinformatics analysis using splice site and SRE predictive matrices was performed to investigate the major factors determining the splicing pathway in splice site mutations and the ability of available algorithms to predict exon-skipping events in exonic mutations.

Materials and Methods {#s2}
=====================

Patient selection {#s2a}
-----------------

Dystrophinopathy patients who tested negative for intragenic deletions and duplications were screened for point mutations using genomic DNA or muscle cDNA whole gene sequencing. Male patients were grouped into four phenotypic categories: DMD, BMD, IMD, and XLCM according to clinical presentation, family history, age at onset, progression and age at loss of ambulation (DMD\<13, BMD≥16, IMD ≥13 and \<16). Females expressing myopathic symptoms were reported as MC (manifesting carriers) while unaffected females were reported as AC (asymptomatic carriers). Patients or their parents in case of children gave written individual informed consent to participate in the study. The study was performed in accordance with the ethical standards laid down in the declaration of Helsinki and was approved by the Ethics Committee of Hospital de la Santa Creu i Sant Pau (HSCSP), Barcelona.

Muscle biopsy analysis {#s2b}
----------------------

A muscle biopsy was taken in 89 out of 105 cases. Muscle sections were analyzed using standard histological and immunohistochemical techniques, described elsewhere. Dystrophin IHC was performed using monoclonal antibodies against N-terminal (DYS3), rod-domain (DYS1) and C-terminal (DYS2) epitopes (Novocastra, Newcastle upon Tyne, UK). IHC analysis of other sarcolemmal proteins, such as α, β, γ and δ sarcoglycans, caveolin-3, dysferlin, utrophin and emerin, were also performed.

Mutation detection {#s2c}
------------------

DNA was extracted from peripheral blood samples according to standard procedures. Prior to point mutation screening, DNA was tested for intragenic deletions and duplications by MLPA (multiple ligation-dependent probe amplification) (P034 and P035 Salsa Kit, MRC-Holland). Point mutation detection was performed on genomic DNA by direct sequencing of the 79 *DMD* exons and their flanking intronic sequences using SCAIP (single-condition amplification/internal primer) [@pone.0059916-Flanigan1]. When muscle tissue was available, mutation analysis was first performed by cDNA sequencing and further confirmed on genomic DNA. Total mRNA was extracted and purified from approximately 30 mg of muscle using RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany) and subsequently retrotranscribed to cDNA by RT-PCR using polythymine primers (Invitrogen, Carlsbad, NM). Complete *DMD* cDNA was amplified and sequenced in twenty overlapping fragments using published [@pone.0059916-Deburgrave1] and self-designed primers. Sequencing analysis were performed using Big Dye 3.1 chemistry and ABI 3500×L equipment (Applied Biosystems, Foster City, CA). Nucleotide positions were determined according to the standard *DMD* reference sequence (GenBank accession number NM_004006.2), and mutation nomenclature follows the guidelines of the Human Genome Variation Society. In order to make data publicly available, mutations and associated phenotypic information were subtmited to the Leiden Open Variant Database (LOVD, [www.dmd.nl](http://www.dmd.nl)), Leiden, the Neetherlands.

Bioinformatics analysis {#s2d}
-----------------------

In silico analysis of wild-type and mutant sequences was performed using a variety of tools integrated in the Human Splicing Finder (HSF, <http://www.umd.be/HSF/>) [@pone.0059916-Desmet1] to identify potential splicing alterations. Acceptor (3′ ss) and donor (5′ ss) splice sites strength was scored using HSF [@pone.0059916-Desmet1], MaxEnt [@pone.0059916-Yeo1] and NNSPLICE [@pone.0059916-Reese1] and SpliceSiteFinder (<http://www.genet.sickkids.on.ca/ali/splicesitefinder.html>) [@pone.0059916-Shapiro1] matrices. These programs were used to predict disruption/creation of splice sites and identification of potential cryptic splice sites. Analysis SRE was done using different matrices that predict exonic splicing enhancer motifs (ESE), silencers motifs (ESS) or both: ESE-finder matrices for SR (serine/arginine-rich) protein binding sites [@pone.0059916-Cartegni2], [@pone.0059916-Smith1], Rescue-ESE hexamers [@pone.0059916-Fairbrother1], PESE and PESS octamers [@pone.0059916-Zhang1], EIE (exonic identity elements) and IIE (intronic identity elements) hexamers [@pone.0059916-Zhang2], Sironi\'s ESS motifs [@pone.0059916-Sironi1], Whang\'s ESS decamers and Fas-ESS hexamers [@pone.0059916-Wang1], and Tra2b, 9G8, and hnRNP A1 binding site matrices [@pone.0059916-Desmet1]. These tools were used to predict mutation-associated SRE disruption/creation and to calculate the density of ESE and ESS motifs in wild-type *DMD* exons. The pathogenicity of amino acid substitutions was evaluated using four algorithms: Polyphen-2 [@pone.0059916-Adzhubei1], SIFT [@pone.0059916-Kumar1], Panther [@pone.0059916-Thomas1] and SNAP [@pone.0059916-Bromberg1].

Statistical analysis {#s2e}
--------------------

The association between alteration of SRE motifs and milder BMD phenotype in truncating mutations was analyzed using Fisher\'s exact test for each SRE predictive matrix ([Table S1](#pone.0059916.s001){ref-type="supplementary-material"}). A permutation test was applied to significant SRE matrices to adjust for multiple comparisons. Differences in relative 5′ splice site strength and density of SRE motifs between exons exhibiting cryptic site activation and exon-skipping in 5′ ss mutations were analyzed using a paired T test.

Analysis of splicing pathways {#s2f}
-----------------------------

Mutations predicted to affect splice sites or SRE motifs were analyzed by semi-quantitative QF-PCR in muscle cDNA. For each mutation, specific fluorescent labelled primers pairs encompassing the mutated exon were designed ([Table S2](#pone.0059916.s002){ref-type="supplementary-material"}). PCR products were analyzed by capillary electrophoresis using ABI 3500×L equipment and Genemapper software (Applied Biosystems, Foster City, CA). Splicing outcomes were determined by comparing fragment length with position of potential cryptic splice sites and exon length. Peak area was used to calculate the relative ratio of each transcript population. Samples were run in duplicate together with a normal control.

Results {#s3}
=======

We identified 98 different point mutations in 105 unrelated dystrophinopathy patients, 99 males and 6 female carriers. [Table 1](#pone-0059916-t001){ref-type="table"} shows the identified mutations and associated muscular phenotypes together with results regarding muscle dystrophin immunostaining and mRNA analysis. Representative images of dystrophin immunostaining are shown in [Figure 1](#pone-0059916-g001){ref-type="fig"}. We identified 54 nonsense mutations, 15 small deletions, 11 insertion/duplications, 20 splice site mutations, 4 missense mutations, and one deep intronic mutation. Aberrant splicing was found in 27 mutations through muscle cDNA and/or in silico analyses. Mechanisms involved in splicing defects included abrogation of 17 natural splice sites, two splice site creations, seven SRE alterations and one pseudoexon activation. In the male patients, 75 had DMD, 15 BMD, 8 IMD and one XLCM. In the female carriers, one was asymptomatic (AC) while five manifested myopathic symptoms (MC). The manifesting carriers reported here were included in a previous work concerning clinical outcomes and X-chromosome inactivation [@pone.0059916-JuanMateu1].

![Representative results of dystrophin immunostaining.\
A healthy control and five patients presenting different types of *DMD* point mutations are shown. BMD patient \#1665 shows dystrophin reduction. This patient presented a 3′ ss disrupting mutation causing mainly exon 3 in-frame skipping. Patient \#1973 presents the rare combination of DMD phenotype and reduction of dystrophin expression. In this patient, a missense mutation in CH1 of ABD1 domain may cause impaired actin-binding activity. DMD patient \#1775 carrying a nonsense mutation in exon 26 shows absence of dystrophin (an isolated revertant fibre can be observed in DYS2). In contrast, patient \#1472 carrying a nonsense mutation in exon 28 shows reduced dystrophin expression and milder BMD phenotype. mRNA analysis in this patient revealed in-frame exon-skipping due to the disruption of an ESE motif. In the last row, BMD patient \#1497 shows a very mild reduction of dystrophin expression. This patient presented a missense mutation in the ZZ domain that may compromise β-distroglycan binding.](pone.0059916.g001){#pone-0059916-g001}
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###### Summary of *DMD* point mutations, clinical phenotype and muscle dystrophin immunostaining in 105 dystrophinopathy patients.

![](pone.0059916.t001){#pone-0059916-t001-1}

  Patient                                              Phenotypic group                                 Dystrophin immunolabelling                                         Mutation at genomic DNA level                                        RT-PCR Fragments                                                Mutation at protein level                   Exon   Protein Domain   Mutation frameness   Exon frameness
  --------------------------------------------------- ------------------ ----------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------- ------ ---------------- -------------------- ----------------
  **Nonsense mutations**                                                                                                                                                                                                                                                                                                                                                                                
  664                                                        DMD                                                  Absence                                                            c.433C\>T                                                      r.433c\>u                                                           p.Arg145X                            6        ABD: CH2             out                out
  1279                                                       DMD                           Decreased intensity of DYS1 and DYS2, absence of DYS3                                     c.583C\>T                                                    Not performed                                                         p.Arg195X                            7        ABD: CH2             out                out
  918                                                        DMD                                                  Absence                                                            c.583C\>T                                                      r.583c\>u                                                           p.Arg195X                            7        ABD: CH2             out                out
  1614                                                        MC                                  Absence with 1--15% of positive fibres                                      \[c.724 C\>T\] + \[ = \]                                              r.724c\>u                                                           p.Gln242X                            8        ABD: CH2             out                out
  468                                                        BMD                                               Not performed                                                         c.883C\>T                                                    Not performed                                                         p.Arg295X                            9           H1                out                 in
  1960                                                       DMD                                                  Absence                                                            c.1388G\>A                                                    r.1388g\>a                                                           p.Trp463X                            12          R2                out                out
  1953                                                       DMD                                                  Absence                                                            c.1474C\>T                                                    r.1474c\>u                                                           p.Gln492X                            12          R2                out                out
  1520                                                       DMD                                                  Absence                                                           \*c.1510C\>T                                                   r.1510c\>u                                                           p.Gln504X                            13          R2                out                 in
  1957                                                       DMD                                  Absence with isolated revertant fibres                                            \*c.1638G\>A                                                   r.1638g\>a                                                           p.Trp546X                            14          R2                out                 in
  1252                                                       DMD                                                  Absence                                                           \*c.2032C\>T                                                   r.2032c\>u                                                           p.Gln678X                            17          H2                out                out
  1774                                                       DMD                                                  Absence                                                           \*c.2215G\>T                                                   r.2215g\>u                                                           p.Glu739X                            18          R4                out                out
  820                                                        DMD                                                  Absence                                                            c.2227C\>T                                                    r.2227c\>u                                                           p.Gln743X                            18          R4                out                out
  1490                                                       DMD                          Absence of DYS1, decreased intensity of DYS2 and DYS 3                                    \*c.2518C\>T                                                   r.2518c\>u                                                           p.Gln840X                            20          R5                out                out
  1986                                                       DMD                                    Absence with 3% of revertant fibres                                             \*c.2560A\>T                                                   r.2560a\>u                                                           p.Lys854X                            20          R5                out                out
  1435                                                       DMD                                                  Absence                                                            c.3427C\>T                                                    r.3427c\>u                                                           p.Gln1143X                           25          R7                out                 in
  1900                                                       DMD                                    Absence with \<1% revertant fibres                                              \*c.3511G\>T                                                   r.3511g\>u                                                           p.Glu1171X                           26          R8                out                 in
  1775                                                       DMD                                  Absence with isolated revertant fibres                                            \*c.3578T\>A                                                   r.3578u\>a                                                           p.Leu1193X                           26          R8                out                 in
  1643                                                        AC                                         Isolated negative fibres                                             \[c.3622C\>T\] + \[ = \]                                        r.\[ =  , 3622c\>u\]                                                      p.Gln1208X                           27          R8                out                 in
  1472                                                       BMD                                            Decreased intesity                                                      \*c.3850G\>T                                   r.\[3850g\>t; 3787_3921del; 3787_4071del\]                     p.\[Glu1284X; Glu1263_Asp1307del; Glu1263_Glu1357del\]     28          R9               in/out               in
  1491                                                       IMD                           Absence of DYS1, decreased intensity of DYS2 and DYS3                                     c.3982C\>T                                      r.\[3982c\>u; 3922_4071; 3787_4071del\]                      p.\[Gln1328X; Glu1263_Asp1307del; Glu1263_Glu1357del\]     29          R9               in/out               in
  1967                                                       DMD                                  Absence with isolated revertant fibres                                             c.4099C\>T                                                    r.4099c\>u                                                           p.Gln1367X                           30          R9                out                 in
  1511                                                       DMD                                                  Absence                                                            c.4527T\>G                                                    r.4527u\>g                                                           p.Tyr1509X                           33         R11                out                 in
  128                                                        DMD                                               Not performed                                                        \*c.4558G\>T                                                  Not performed                                                         p.Glu1520X                           33         R11                out                 in
  1396                                                       DMD                                                 Abesence                                                           \*c.4838G\>A                                                   r.4838g\>a                                                           p.Trp1632X                           34         R12                out                 in
  1580                                                       DMD          Absence of DYS3, pronounced decreased intensity with negative fibres with DYS2 and DYS3                    c.5131C\>T                                                    r.5131c\>u                                                           p.Gln1711X                           36         R13                out                 in
  1958                                                       DMD                                  Absence with isolated revertant fibres                                             c.5131C\>T                                                    r.5131c\>u                                                           p.Gln1711X                           36         R13                out                 in
  1976                                                       DMD                                  Absence with isolated revertant fibres                                            \*c.5308A\>T                                                   r.5308a\>u                                                           p.Arg1770X                           37         R13                out                 in
  548                                                        BMD                             Decreased intensity with isolated negative fibres                                       c.5287C\>T                                           r.\[5287c\>u; 5155_5325del\]                                     p.\[Arg1763X ; Arg1719_Lys1775del\]               37         R13               in/out               in
  1728                                                       BMD                                   Decreased intensity in mosaic pattern                                             c.5287C\>T                                           r.\[5287c\>u; 5155_5325del\]                                     p.\[Arg1763X ; Arg1719_Lys1775del\]               37         R13               in/out               in
  1097                                                       IMD                                               Not performed                                                         c.5371C\>T                                                   Not performed                                                         p.Gln1791X                           38         R14                out                 in
  1624                                                       DMD                                                  Absence                                                            c.5530C\>T                                                    r.5530c\>u                                                           p.Arg1844X                           39         R14                out                 in
  1691                                                       DMD                                                  Absence                                                            c.5530C\>T                                                    r.5530c\>u                                                           p.Arg1844X                           39         R14                out                 in
  975                                                        DMD                                                  Absence                                                           \*c.5611A\>T                                                   r.5611a\>u                                                           p.Lys1871X                           40         R14                out                 in
  374                                                        DMD                                                  Absence                                                            c.5646C\>A                                                    r.5646c\>a                                                           p.Tyr1882X                           40         R15                out                 in
  1221                                                        MC                             Isolated negative and decreased intensity fibres                                 \[ = \] ; \[c.5893C\>T\]                                        r.\[ =  ; 5893c\>u\]                                                 p.\[ = ; Gln1965X\]                       41         R15                out                 in
  444                                                        DMD                                               Not performed                                                         c.6283C\>T                                                   Not performed                                                         p.Arg2095X                           43         R16                out                out
  1461                                                      XL-CM                                 Mosaic pattern with 8% negative fibres                                        c.\[ = ; 6292C\>T\]                                            r.\[ = ;6292c\>u\]                                                   p.\[ = ;Arg2098X\]                       44         R16                out                out
  1743                                                       DMD                                  Absence with isolated revertant fibres                                             c.6292C\>T                                                   Not performed                                                         p.Arg2098X                           44         R16                out                out
  1837                                                       DMD                                               Not performed                                                        \*c.6352C\>T                                                  Not performed                                                         p.Gln2118X                           44         R17                out                out
  1970                                                       DMD                                                  Absence                                                            c.6973C\>T                                                    r.6973c\>u                                                           p.Gln2325X                           48         R19                out                 in
  1954                                                       DMD                                                  Absence                                                            c.7564C\>T                                                   Not performed                                                         p.Gln2522X                           52         R20                out                out
  1457                                                       DMD                                                  Absence                                                            c.7657C\>T                                                    r.7657c\>u                                                           p.Arg2553X                           52         R20                out                out
  101                                                        DMD                                               Not performed                                                         c.7657C\>T                                                   Not performed                                                         p.Arg2553X                           52         R20                out                out
  466                                                        DMD                                                  Absence                                                            c.8608C\>T                                                    r.8608c\>u                                                           p.Arg2870X                           58         R23                out                out
  602                                                        DMD                                                  Absence                                                            c.8713C\>T                                                    r.8713c\>u                                                           p.Arg2905X                           59         R23                out                out
  1256                                                       DMD                                                  Absence                                                            c.8944C\>T                                                    r.8944c\>u                                                           p.Arg2982X                           60         R24                out                 in
  1955                                                       DMD                                                  Absence                                                            c.9100C\>T                                                    r.9100c\>u                                                           p.Arg3034X                           61         R24                out                out
  1523                                                       DMD                                                  Absence                                                            c.9148C\>T                                                    r.9148c\>u                                                           p.Gln3050X                           61          H4                out                out
  1175                                                       DMD                                               Not performed                                                         c.9337C\>T                                                   Not performed                                                         p.Arg3113X                           64         CRD                out                 in
  1344                                                       DMD                           Absence of DYS2 and DYS3. Decreased intensity of DYS1                                     c.9380C\>G                                                   Not performed                                                         p.Ser3127X                           65         CRD                out                out
  1754                                                       DMD                                               Not performed                                                        \*c.9542G\>A                                                  Not performed                                                         p.Trp3181X                           65      CRD: EF-2             out                out
  996                                                        DMD                                                  Absence                                                            c.9568C\>T                                                    r.9568c\>u                                                           p.Arg3190X                           66      CRD: EF-2             out                out
  1956                                                       DMD                                                  Absence                                                           c.10033C\>T                                                    r.10033c\>u                                                          p.Arg3345X                           69       CRD: ZZ              out                out
  1965                                                       DMD                                                  Absence                                                          \*c.10147A\>T                                                   r.10147a\>u                                                          p.Lys3383x                           70         CTD                out                out
  **Deletions mutations**                                                                                                                                                                                                                                                                                                                                                                               
  1968                                                       DMD                                                  Absence                                                            \*c.39del                                                    Not performed                                                      p.Glu14LysfsX12                         2        ABD: CH1             out                out
  1839                                                       DMD                                                  Absence                                                          \*c.114_115del                                                 r.114_115del                                                        p.Asn39ProfsX4                         3        ABD: CH1             out                 in
  1558                                                       DMD                                      Pronounced decreased intensity                                                c.174_175del                                                  r.174_175del                                                       p.Gly59Ala_fsX29                        3        ABD: CH1             out                 in
  1556                                                       DMD                                                  Absence                                                           \*c.5613del                                                   not performed                                                      p.Ala1872LeufsX2                        40         R14                out                 in
  1966                                                       DMD                                                  Absence                                                           \*c.6127del                                                     r.6127del                                                       p.Asp2043IlefsX30                        43         R16                out                out
  1734                                                       DMD                                               not performed                                                       c.6128_6131del                                                 not performed                                                     p.Asp2043ValfsX29                        43         R16                out                out
  1729                                                       DMD                                    Absence with 4% of revertant fibres                                           \*c.6580_6614del                                               r.6580_6614del                                                     p.Glu2194Ala_fsX17                       45         R17                out                out
  1314                                                        MC                                         Isolated negative fibres                                            \*\[c.6638del\] + \[ = \]                                         r.\[ =  , 6638del\]                                                   p.Leu2213CysfsX8                        46         R18                out                out
  1963                                                       DMD                                                  Absence                                                         \*c.8034_8037del                                               r.8034_8037del                                                     p.Glu2681LeufsX44                        55         R21                out                out
  1974                                                       DMD                                                  Absence                                                           \*c.9862del                                                     r.9862del                                                       p.Glu3288AsnfsX42                        68         CRD                out                out
  1547                                                       DMD                                                  Absence                                                           \*c.9885del                                                     r.9885del                                                       p.Val3297SerfsX33                        68         CRD                out                out
  1972                                                       DMD                        End-stage muscular dystrophy, dystrophin IHC not evaluable                                c.10101_10103del                                              r.10101_10103del                                                       p.Glu3367del                          70         CTD                 in                out
  1242                                                       BMD                                               Not performed                                                     \*c.10231_10235del                                               Not performed                                                     p.Thr3411AspfsX20                        71         CTD                out                 in
  605                                                        BMD                           Absence of DYS2, decreased intensity of DYS1 and DYS3                                    \*c.10235del                                         r.\[10235del; 10224_10262del\]                                  p.\[Leu3412ArgfsX7; Pro3409_Ala3421del\]            71         CTD               in/out               in
  1961                                                       DMD                                                  Absence                                                        \*c.10624_10625del                                             r.10624_10625del                                                     p.Pro3542SerfsX2                        75         CTD                out                out
  **Duplications, insertions and delins mutations**                                                                                                                                                                                                                                                                                                                                                     
  1990                                                       DMD                                               Not performed                                        \*c.1183_1186delins18 \[Alu-like insertion\]                                  Not performed                                                      p.Arg395CysfsX17                        11          R1                out                out
  1862                                                       DMD                                               Not performed                                                        \*c.1510dup                                                   Not performed                                                      p.Gln504ProfsX15                        13          R2                out                 in
  22                                                          MC                        End-stage muscular dystrophy, dystrophin IHC not avaluable                                \*c.2095delinsTC                                                Not performed                                                      p.Ala699SerfsX21                        17          H2                out                out
  1741                                                       DMD                                               Not performed                                                        \*c.2667dup                                                   Not performed                                                      p.Leu890IlefsX30                        21          R5                out                out
  1521                                                       DMD                                                  Absence                                                      \*c.5139_c.5140delinsT                                        r.5139_c.5140delag_insu                                                 p.Lys1713AsnfsX8                        36         R13                out                 in
  1632                                                       IMD                                  Absence with isolated revertant fibres                                            \*c.7360dup                                                     r.7360dup                                                       p.Thr2454AsnfsX37                        51          H3                out                out
  1735                                                       DMD                                               Not performed                                                   \*c.8711_8715delinsAGG                                             Not performed                                                      p.Leu2904GlnfsX5                        59         R23                out                out
  1148                                                       DMD                                                  Absence                                                           \*c.8955dup                                                   Not performed                                                     p.Ala2986CysfsX12                        60         R24                out                 in
  1646                                                       DMD                                               Not performed                                                        \*c.9348dup                                                   Not performed                                                     p.Lys3117GlufsX15                        64         CRD                out                 in
  1964                                                       DMD                                  Absence with isolated revertand fibres                                         \*c.9583_9584insAT                                             r.9583_9584insat                                                    p.Arg3195HisfsX89                        66      CRD: EF-2             out                out
  1736                                                       BMD          Decreased intensity with DYS1 and DYS2. Absence of DYS3 with isolated positive fibres.                    \*c.10409dup                                                  Not performed                                                     p.Leu3470PhefsX21                        74       CTD: SBS             out                 in
  **Splice site mutations**                                                                                                                                                                                                                                                                                                                                                                             
  1665                                                       BMD                                            Decreased intensity                                                      c.94-1G\>T                                            r.\[94_105del; 94_186del\]                                      p.\[Phe32_Gln35del; Phe32_Leu62del\]              3        ABD: CH1              in                 in
  2042                                                       IMD                                            Decreased intensity                                                    \*c.265-1G\>A                                            r.\[265del; 265_367del\]                                       p.\[Val89LeufsX3; Val89_Gln119del\]               5        ABD: CH1            in/out               in
  1849                                                       DMD                                                  Absence                                                          \*c.358-1G\>C                                                  Not performed                                                           p.spl                              6        ABD: CH2              ?                 out
  1753                                                       IMD                                  Absence with isolated revertand fibres                                           \*c.961-1G\>A                                                  Not performed                                                           p.spl                              10          R1                 ?                  in
  1971                                                       DMD                                                  Absence                                                           c.1332-9A\>G                   r.\[ = ; 1331_1332ins1332-8_1332-1; 1332_1359del; 1332_1482del; 1332_1602\]   p.\[ = ; Asn444LysfsX9; Asn444LysfsX5; p.Asn444LysfsX7\]    12         R1-2              in/out              out
  1982                                                       DMD                                                  Absence                                                           c.1332-9A\>G                   r.\[ = ; 1331_1332ins1332-8_1332-1; 1332_1359del; 1332_1482del; 1332_1602\]   p.\[ = ; Asn444LysfsX9; Asn444LysfsX5; p.Asn444LysfsX7\]    12         R1-2              in/out              out
  338                                                        BMD                                            Decreased intensity                                                    \*c.1704+2T\>A                       r.\[ = ; 1704_1705ins1704+1_1704+11; 1704_1705ins1704+1_1705-1\]                 p.\[ = ; Cys569ValfsX18; Cys569ValfsX5\]            14          R3               in/out               in
  1746                                                       DMD                                                  Absence                                                          \*c.2169-2A\>G                                                 Not performed                                                           p.spl                              18          R4                 ?                 out
  1959                                                       DMD                                                  Absence                                                          \*c.2803+1del                                        r.\[2623_2803del; 2757_2803del\]                                   p.\[Asp875PhefsX14; Lys919AsnfsX3\]               21         R5-6               out                out
  1342                                                       BMD                                            Decreased intensity                                                    \*c.3432+3A\>T                                               r.3277_r.3432del                                                   p.Leu1093_Gln1144del                      25          R7                 in                 in
  642                                                        DMD                                                  Absence                                                          \*c.3603+1G\>A                                   r.3603_3604ins3603+1_3603+116{3603+1G\>A}                                       p.Arg1202ValfsX25                        26          R8                out                 in
  1061                                                       BMD                         Absence of DYS2. Near normal intensity of DYS1 and DYS3.                                   c.3603+2dupT                                r\[ = ; 3603_3604ins3603+1_3603+116{3603+1G\>A}\]                               p.\[ = ; Arg1202ValfsX25\]                   26          R8               in/out               in
  520                                                        BMD                             Decreased intensity with isolated negative fibres                                     \*c.3786+1G\>A                                       r.\[3604_3786del; 3604_4071del\]                               p.\[Arg1202_Glu1262del; Arg1202_Glu1357del\]          27          R8                 in                 in
  1915                                                       IMD                                            Decreased intensity                                                     c.4845+1G\>A                                                  Not performed                                                           p.spl                              34         R12                 ?                  in
  1339                                                       DMD                                                  Absence                                                           \*c.5444A\>G                                                r.5444_r.5448del                                                     p.Asp1815GlufsX2                        38         R14                out                 in
  1962                                                       DMD                                  Absence with isolated revertand fibres                                           \*c.6614+1G\>T                                                 Not performed                                                           p.spl                              45         R17                 ?                 out
  632                                                         MC                                Mosaic pattern with 20% of negative fibres                                   \[c.6913-1G\>A\] + \[ = \]                                        r.\[ =  , 6913del\]                                              p.\[ = ; Val2305PhefsX16\]                   48         R18                out                 in
  1606                                                       DMD                                                  Absence                                                           c.9563+1G\>A                                                  Not performed                                                           p.spl                              65      CRD: EF-2              ?                 out
  1619                                                       BMD                                 Decreased intensity with negative fibres                                          \*c.9563+5G\>C                              r.\[ = ; 9560_9563del; 9563_9564ins9563+1_9563+9\]                p.\[ = ; Asp3187GlyfsX95; Thr3188_Gly3189insTyrValTrp\]     65      CRD: EF-2            in/out              out
  1455                                                       DMD                                                  Absence                                                          c.10086+5G\>C                                     r.\[ = ; 9975_10086del; 9808_10086del\]                          p.\[ = ; Tyr3326LeufsX14; Ala3270_Pro3362del\]         69       CRD: ZZ             in/out              out
  **Deep Intronic mutations**                                                                                                                                                                                                                                                                                                                                                                           
  1465                                                       BMD                                            Decreased intensity                                                    c.9225-647A\>G                                   r.\[ = ; 9224_9225ins9225-713_9225-647\]                                    p.\[ = ; Asn3075LysfsX3\]                   i62       CRD: WW             in/out              n.a.
  **Missense mutations**                                                                                                                                                                                                                                                                                                                                                                                
  1973                                                       DMD                       Decreased intensity with normal and negative isolated fibres                                 \*c.158T\>G                                                     r.158u\>g                                                           p.Leu53Arg                           3        ABD: CH1              in                 in
  1755                                                       IMD                                               Not performed                                                        \*c.497G\>T                                                   Not performed                                                        p.Gly166Val                           6        ABD: CH2              in                out
  1215                                                       IMD                                 Decreased intensity with negative fibres                                     \*c.1350_1351delGGinsAT                                         r.1350_1351delgginsat                                               p.Met450Ile_Asp451Tyr                      12          R1                 in                out
  1497                                                       BMD                       Mildly decreased intensity of DYS3, DYS1 and DYS2 near normal                                \*c.9958C\>T                                                   r.9958c\>u                                                          p.Pro3320Ser                          68       CRD: ZZ               in                out

Asterisks indicate novel mutations not previously reported in the LOVD ([www.dmd.nl](http://www.dmd.nl)). Protein domains: ABD, actin-binding domain; CH1-2, calponin homology; R1-24, spectrin-like repeats; H1-4, hinge regions; CRD, cysteine-rich domain; WW, domain with a signature of two tryptophan that binds to proline-rich proteins; EF-1/2, EF-hand domains found in calcium-binding proteins; ZZ, zinc-finger domain; CTD, c-terminal domain; SBS α1-syntrophin-binding site.

The frequency of each type of mutation differed substantially between clinical phenotypes. Most DMD patients presented nonsense and frameshift truncating mutations that accounted for 84% of cases (63/75). Splice site mutations were found in 14.6% of cases (11/75) while missense and in-frame changes were found in 2.7% (2/75). BMD patients presented the same proportion of truncating mutations than splicing defects, 46.7% (7/15) each. Splicing defects in BMD include a pseudoexon activation caused by a deep intronic substitution. Only one missense mutation was detected in BMD patients (6.7%). IMD patients presented three truncating mutations (37.5%), three splice site mutations (37.5%) and two missense mutations (25%).

Nonsense and frameshift mutations {#s3a}
---------------------------------

The great majority of truncating mutations identified in male patients were associated with more severe DMD and IMD phenotypes (66/74, 89.2%). However, 8 patients exhibiting BMD or XLCM phenotypes presented nonsense or frameshift mutations (11%). Patient \#444, presenting isolated DCM but no muscle weakness, carried a nonsense mutation in somatic mosaicism. BMD patients \#468, \#1472, \#548, \#1728, \#1242, \#605 and \#1736 presented six different mutations localized in five in-frame skippable exons (exons 9, 28, 37, 71 and 74). Three of these mutations were found to induce significant amounts of in-frame exon-skipping in muscle cDNA ([Figure 2](#pone-0059916-g002){ref-type="fig"}). Patient \#1472 presenting c.3850G\>T in exon 28, showed ∼4% of exon 28 skipping and ∼35% of exons 28 and 29 double skipping. Patients \#548 and \#1728 carrying c.5287C\>T in exon 37, showed ∼29% of exon 37 skipping. Patient \#605 presenting c.10235del in exon 71, showed ∼21% of exon 71 skipping. In addition, in-frame exon-skipping was also found in an IMD patient (\#1491). This patient carrying c.3982C\>T nonsense mutation in exon 29, showed ∼2% of exon 29 skipping and ∼9% of exon 28 and 29 double skipping.

![Exonic mutations associated with exon-skipping events.\
On the left, semi-quantification of alternative transcripts by QF-PCR on muscle biopsy cDNA. In the centre, schematic representation of the detected transcript species and their relative ratio. On the right, mutation sequence context and predicted ESE motifs: blue bars indicate ESE finder SR protein binding sites; violet bars indicate Rescue-ESE hexamers; red bars indicate PESE octamers. The mutated nucleotide is indicated in red.](pone.0059916.g002){#pone-0059916-g002}

In silico analysis of SRE motifs showed five ESE disruptions and one ESS creation in BMD mutations. Disruption of at least one PESE octamer occurred in mutations c.883C\>T (exon 9), c.3850G\>T (exon 28), c.5287C\>T (exon 37), c.10235del (exon 71) and c.10231_10235del (exon 71). Mutation c.10409dup (exon 74) was predicted to create an ESS according to PESS and Fas-ESS matrices. Five BMD mutations were predicted to create an intronic identity element (IIE). IMD mutation c.3982C\>T (exon 29) was predicted to disrupt three SR-protein binding sites and to create an ESS according to hnRNP A1 and Sironi\'s matrices ([Table S1](#pone.0059916.s001){ref-type="supplementary-material"}). To investigate the ability of available matrices to predict critical regions for exon recognition and, to assess the association of SRE alterations with exon-skipping in BMD patients, all truncating mutations located in in-frame exons were tested against different matrices ([Table S1](#pone.0059916.s001){ref-type="supplementary-material"}). In male patients, 32 nonsense/frameshift mutations were identified in-frame skippable exons but only six were associated with milder BMD phenotype (18.75%). Statistically significant differences between DMD/IMD and BMD mutation groups were found using PESE and IIE matrices. Other matrices did not show any significant difference. Predicted disruption of PESE octamers occurred in 5 out of 6 BMD mutations (83.3%) and in 6 out of 26 DMD/IMD mutations (23%) (Fisher\'s Exact Test, *P*-value 0.0112). Seven mutations associated with DMD/IMD were found in exons where exon skipping events have been previously described (exons 25, 29, 37, 38, and 40). None of them was predicted to disrupt any PESE octamer. Creation of IIE hexamers occurred in 5 of 6 BMD mutations (83.3%) and in 7 of 26 DMD/IMD mutations (26.9%) (Fisher\'s Exact Test, *P*-value 0.0185). A permutation test corroborated the significant result between the PESE and IIE matrices (truncated *P*-value product 0.00659).

Splice site mutations {#s3b}
---------------------

We identified twenty different splice site mutations in twenty-one unrelated patients. Splicing pathways were determined in fourteen mutations through muscle cDNA sequencing and QF-PCR analysis. Detected transcript species, relative ratio and splice site predictions are summarized in [table 2](#pone-0059916-t002){ref-type="table"}. Most mutations involved canonical AG/GT nucleotides disrupting natural splice sites (13/20, 65%). Four involved non-canonical nucleotides (20%), of which one disrupted the splice site while the other three reduced its efficiency. Creation of a new splice site was found in four mutations. Two of them also disrupted a natural site (c.265-1G\>A and c.6913-1G\>A), while the other two (c.1332-9A\>G and c.5444A\>G) created a strong splice site more efficient than the natural site. An intronic single-base substitution far from a natural splice site (647 bp) provoked the activation of a cryptic 5′ ss causing the inclusion of a 67 bp pseudoexon into the mature mRNA. Mutations affecting natural 5′ ss were more frequent (11/21, 52.4%) than those affecting natural 3′ ss (6/21, 28.6%).

10.1371/journal.pone.0059916.t002

###### Splicing pathways in splice site mutations.

![](pone.0059916.t002){#pone-0059916-t002-2}

  Patient      Phenotype     Exon         Mutation                       QF-PCR detected transcripts                     Ratio   HSF score (% variation)   MaxEnt score (% variation)   Transcript frameness
  ----------- ----------- ----------- ---------------- ---------------------------------------------------------------- ------- ------------------------- ---------------------------- ----------------------
  1665            BMD          3         c.94-1G\>T                            Exon 3 skipping                            71%      wt 89.2→60.3 (−32%)        wt 8.3→−0.3 (−103%)                in
                                                               Cryptic 3′ ss activation causing 12 bp deletion            29%             79.2                         0                         in
  2042            IMD          5        c.265-1G\>A                            Exon 5 skipping                            64%        wt 93→64 (−31%)           wt 12.6→3.9 (−69%)                in
                                                                   New 3′ ss creation causing 1 bp deletion               36%       48.7→77.6 (+59%)            −2.3→5.7 (+350%)                out
  1971/1982       DMD         12        c.1332-9A\>G              New 3′ ss creation causing 8 bp inclusion               58%       58.5→87.4 (+50%)            −6.6→2.1 (+132%)                out
                                                                               Exon 12 skipping                           27%              \-                          \-                       out
                                                               Cryptic 3′ ss activation causing 28 bp deletion            6%              83.5                        2.9                       out
                                                                               Normal splicing                            5%      wt 83.1→83.2 (+0.14%)         wt 6.9→1 (−84%)                  in
                                                                           Exon 12 and 13 skipping                        4%               \-                          \-                       out
  338             BMD         14        c.1704+2T\>A         Cryptic GT 5′ ss activation causing 11 bp inclusion          60%             78.8                        0.5                       out
                                                          Usage of exon 15 natural 5′ ss causing intron 14 retention      28%            wt 73.7                     wt 6.4                     out
                                                                               Normal splicing                            12%       wt 90→63.2 (−30%)          wt 7→−1.2 (−117%)                 in
  1959            DMD         21        c.2803+1del                            Exon 21 skipping                           88%      wt 89.4→12.8 (−86%)        wt 10.1→−20 (−299%)               out
                                                              Cryptic GC 5′ ss activation causing 47 bp deletion          12%               0                          0                        out
  1342            BMD         25        c.3432+3A\>T                           Exon 25 skipping                          100%      wt 77.1→72.1 (−7%)          wt 8.7→3.1 (−64%)                 in
  642             DMD         26        c.3603+1G\>A         Cryptic GT 5′ ss activation causing 116 bp inclusion        100%      wt 84.6→57.7 (−37%)         wt 8.4→0.2 (−98%)                out
                                                                                                                                          72.7                        1.5              
  1061            BMD         26        c.3603+2dupT                           Normal splicing                            83%      wt 84.6→79.5 (−6%)          wt 8.4→2.7 (−68%)                 in
                                                             Cryptic GT 5′ ss activation causing 116 bp inclusion         17%             72.7                        1.5                       out
  520             BMD         27        c.3786+1G\>A                           Exon 27 skipping                           80%      wt 82.6→55.8 (−32%)         wt 1→−7.2 (−801%)                 in
                                                                         Exon 27, 28 and 29 skipping                      20%              \-                          \-                        in
  1339            DMD         38         c.5444A\>G                   New GT 5′ ss creation causing 5 bp                 100%       61.5→88.3 (+44%)            1.1→9.3 (+757%)                 out
  632             MC          48        c.6913-1G\>A               New 3′ ss creation causing 1 bp deletion              100%      wt 98.7→69.7 (−29%)         wt 10.1→1.3 (−87%)               out
                                                                                                                                    55.1→84.1 (+53%)           −1.54→6.41 (+516%)      
  1619            BMD         65        c.9563+5G\>C                           Normal splicing                            49%      wt 78.2→66.2 (−15%)         wt 6.8→1.3 (−81%)                 in
                                                                               Deletion of 4 bp                           26%               0                          0                        out
                                                              Cryptic GC 5′ ss activation causing 9 bp inclusion          25%               0                          0                         in
  1455            DMD         69       c.10086+5G\>C                           Exon 69 skipping                           46%              \-                          \-                       out
                                                                           Exon 68 and 69 skipping                        46%              \-                          \-                        in
                                                                               Normal splicing                            8%       wt 95.3→83.2 (−13%)        wt 10.9→−41.4 (−41%)               in
  1465            BMD      intron 62   c.9225-647A\>G   Cryptic GT 5′ ss activation causing 67 bp pseudoexon inclusion    74%       56.9→85.9 (+51%)            4.4→8.8 (+97.3%)                out
                                                                               Normal splicing                            26%              \-                          \-                        in

Natural (wt) and cryptic splice sites were scored using Human Splicing Finder (HSF) and Maximum Entropy Scan matrices (MaxEnt).

The splicing pathway differed from one mutation to another. In most cases (11/14) variable levels of more than one alternative transcript were detected. Splicing outcomes included exon-skipping, cryptic or new splice site activation, intron retention and pseudoexon inclusion. Six mutations induced exclusively or mainly exon-skipping, seven induced activation of alternative splice sites and one mutation induced predominantly normal splicing (c.3603+2dupT). In most cases, the clinical phenotype and expression of dystrophin correlated with the absence/presence of significant amounts of normal and/or in-frame mRNA transcripts. This correlation was not observed in two cases presenting significant amounts of in-frame transcripts and a severe phenotype (patients \#2042 and \#1455). In both cases, most abundant in-frame transcripts presented truncated protein-binding domains, actin-binding (ABD) or zinc-finger (ZZ) domains respectively. Loss of coding sequences may also have an impact on protein folding or stability. The mutations that abolished the function of natural sites presented a score reduction between 7% and 86% using HSF, and between 64% and 801% using MaxEnt ([Table 2](#pone-0059916-t002){ref-type="table"}). The mutations that reduced the site efficiency presented a score reduction between 7% and 15% using HSF, and between 41% and 81% using MaxEnt. Most of the activated cryptic or new sites were predicted by HSF or MaxEnt matrices ([Table 2](#pone-0059916-t002){ref-type="table"}). However, two transcripts presented activation of GC 5′ ss (\#1959 and \#1619) that were only predicted by the SpliceSiteFinder algorithm. Two transcripts did not correlate with any potential 5′ ss (patients \#338 and \#1619).

To investigate the major factors determining the main alternative splicing pathway in 5′ ss mutations (cryptic site activation versus exon-skipping), we analyzed several parameters: exon and intron length, density of SRE motifs, availability of cryptic sites and relative 3′ ss strength. The analysis was extended to eight exons with previously reported pathways in 5′ ss disrupting mutations [@pone.0059916-Takeshima1]. We found that exons exhibiting mainly exon-skipping presented a weak 3′ ss, while most exons showing predominantly cryptic site activation presented a strong 3′ ss ([Figure 3A](#pone-0059916-g003){ref-type="fig"}, paired t test, *P*-value 0.0346). No statistically significant differences were found in other parameters. However, exons exhibiting cryptic site activation presented a mean density of ESE motifs higher than exon showing exon-skipping ([Figure 3B](#pone-0059916-g003){ref-type="fig"}).

![Factors determining the main splicing pathway in 5′ ss mutations: cryptic site activation versus exon-skipping.\
**A**) Relative 3′ ss strength (MaxEnt score difference with next distal natural 3′ ss) of exons exhibiting mainly cryptic site activation and exon exhibiting mainly exon-skipping. Box plots indicate the lowest and highest observation, lower and upper quartile, and median. **B**) Mean density of ESE motifs predicted by different matrices. **C**) Individual exons are plotted by the relative 3′ ss strength and density of Rescue-ESE motifs. Black-filled circles represent exons showing cryptic site activation. Non-filled circles represent exons showing exon-skipping. Exon numbers are indicated beside circles.](pone.0059916.g003){#pone-0059916-g003}

Missense and in-frame mutations {#s3c}
-------------------------------

Four missense mutations and one amino acid deletion were detected in our cohort. All were located in highly conserved residues and were predicted to be pathogenic based on Polyphen-2 and SIFT algorithms. These mutations were not found in 100 healthy controls and not reported in the Exome Variant Server (<http://evs.gs.washington.edu/EVS/>). Two mutations were found in the N-terminal ABD. In the CH1 (calponin homology ABD domain), mutation p.Leu53Arg was found in a DMD patient with irregularly reduced expression of dystrophin ([Figure 1](#pone-0059916-g001){ref-type="fig"}). In the CH2 domain, mutation p.Gly166Val was found in a patient with IMD. In the central rod-domain at the spectrin-like repeat 2, a double amino acid change (p.Met450Ile_Asp451Tyr) was detected in an IMD patient presenting reduction of dystrophin with negative fibres. Two mutations were found in the C-terminal cysteine-rich region. Mutation p.Pro3320Ser in the ZZ-domain was found in a BMD patient with near normal dystrophin expression ([Figure 1](#pone-0059916-g001){ref-type="fig"}), and a single amino acid deletion, p.Glu3367del, was found in a DMD patient.

Discussion {#s4}
==========

We describe a comprehensive analysis of 98 DMD point mutations related to clinical phenotype and their effect on muscle mRNA and dystrophin expression. Aberrant splicing was found in 27 mutations. Mechanisms responsible for the splicing defects consisted in abrogation of natural splice sites, creation of new splice sites, disruption/creation of regulatory elements (SRE) and pseudoexon activation. Bioinformatics analysis of nonsense/frameshift mutations revealed that PESE/PESS matrix is a powerful tool to predict critical regulatory regions for BMD-associated exon-skipping. Our findings suggest that the splicing pathway in 5′ ss disrupting mutations is highly dependent on the interplay between 3′ ss strength and density of exonic splicing enhancers.

In agreement with the reading frame rule, most nonsense and frameshift mutations in our cohort were found in patients presenting a severe DMD or IMD phenotype. However, 11% of them were detected in patients presenting milder BMD or XLCM phenotypes. Several mechanisms have been associated with the production of dystrophin in nonsense/frameshift mutations, ameliorating the clinical phenotype. These include alternative translation initiation in 5′ end mutations [@pone.0059916-Winnard1], [@pone.0059916-Gurvich1], escape of nonsense-mediated mRNA decay (NMD) in mutations located in or beyond exon 74 [@pone.0059916-Kerr1] and somatic mosaicism [@pone.0059916-Deburgrave1], [@pone.0059916-HeldermanvandenEnden1], [@pone.0059916-Kesari1]. However, the most reported mechanism is the skipping of the mutated exon, producing significant amounts of in-frame transcripts. Mechanisms involved in exon-skipping events include disruption and creation of SRE. Although creation of ESS has been reported [@pone.0059916-Disset1], disruption of ESE is better documented [@pone.0059916-Shiga1]--[@pone.0059916-Ginjaar1], [@pone.0059916-Deburgrave1], [@pone.0059916-Fajkusova1]. Most widely used algorithms to predict ESE disruption are ESE Finder matrices for SR protein binding sites, and Rescue-ESE hexamers which are differentially present in exons and introns. However, the ability of these tools to predict exon-skipping events in the *DMD* gene is limited. Analysis of the mutation entries in the Leiden database (LOVD) revealed that ESE disruption occurred in 50% of BMD nonsense mutations [@pone.0059916-AartsmaRus2]. Deburgrave et al. reported similar results, since 4 out of 8 mutations with confirmed mRNA exon-skipping had consequences on ESE motifs ESE motifs [@pone.0059916-Deburgrave1].

In our subset of patients, we found a nonsense mutation in somatic mosaicism in a patient who presented DCM but no muscle weakness. Clinical, pathological and molecular studies in this patient are discussed in greater detail in a previous work [@pone.0059916-JuanMateu2]. Exon-skipping events were found or predicted in seven BMD patients. We found that 8-mers putative splicing enhancers (PESE) and silencers (PESS) from Zhang and Chasin [@pone.0059916-Zhang1] are a powerful tool to predict in the *DMD* gene critical SRE motifs for exon recognition. PESE disruption was predicted in six patients presenting five different mutations. Disruption of ESE motifs was predicted only in one mutation when ESE finder or Rescue-ESE matrices were used ([Figure 2](#pone-0059916-g002){ref-type="fig"} and [Table S1](#pone.0059916.s001){ref-type="supplementary-material"}). Surprisingly, disruption of PESE motifs in BMD overlapped in most cases with creation of an intronic identity element (IIE) [@pone.0059916-Zhang2], raising the possibility that the mutations had a double effect, contributing to loss of exon identity. An ESS creation was predicted by PESS and other matrices in a nonsense mutation in exon 74. However, in absence of cDNA studies we can not confirm an exon-skipping event, since mutations in this exon have been found to cause either exon-skipping or escape from NMD [@pone.0059916-TufferyGiraud2], [@pone.0059916-Deburgrave1]. None of the associated IMD/DMD mutations located in exons where exon-skipping events have previously been reported were predicted to disrupt any PESE octamer. However, one of these mutations located in exon 29 induced exon-skipping. Nevertheless, the proportion of exon-skipping transcripts in the patient was much lower than those found in a BMD patient presenting an identical skipping pattern ([Figure 2](#pone-0059916-g002){ref-type="fig"}), indicating that they are insufficient to rescue the phenotype. According to LOVD this mutation has been previously found in BMD patients, suggesting differences in the exon-skipping efficiency between individuals. In line with this hypothesis, Ginjaar et al. reported a BMD family with a nonsense mutation in exon 29 who presented variable phenotype severity, ranging from severe BMD to asymptomatic elevation of CK levels [@pone.0059916-Ginjaar1]. The authors reported that clinical variability was related to different levels of exon 29 skipping.

In line with previous reports [@pone.0059916-Tran1]--[@pone.0059916-Cartegni1], our data indicate that SRE disruption/creation is not the only factor determining exon-skipping, since 6 out of 11 mutations disrupting PESE octamers in in-frame exons were found in IMD/DMD patients ([Table S1](#pone.0059916.s001){ref-type="supplementary-material"}). In a recent work, Flanigan et al. 2011 reported that exon-skipping occurs in a subset of exons, proposing a model in which a weak exon definition context, defined by a weak 3′ ss and low ESE density, is necessary for mutation-associated exon-skipping [@pone.0059916-Flanigan2]. In our cohort, we identified BMD nonsense/frameshift mutations in exons 9, 28, 37, 71 and 74. To our knowledge, this is the first report of exon-skipping events in exons 9 and 28. According to the model of Flanigan et al, exons 37 and 71 present weak 3′ ss and a low ESE density, while exon 9 exhibits the lowest ESE density in our subset of exons ([Figure 4](#pone-0059916-g004){ref-type="fig"}). Exons 28 and 74, however, present high ESE densities and strong acceptor splice sites. Furthermore, in exons 3 and 33, presenting a weak exon definition context similar to other skipped exons, PESE disruption does not induce exon-skipping as cDNA analysis or the patient\'s phenotype indicate. Our data suggest that factors other than a weak 3′ ss and low ESE density may also influence the skipping capability of exons. The genomic context probably displays a relevant role in many exons. Mutations c.3850G\>T (exon 28) and c.3982C\>T (exon 29) induce both double skipping of exon 28 and 29, while mutation c.3786+1G\>A (exon 27) produces significant amounts of transcripts showing skipping of exons 27 to 29. Other splice site mutations, such as c.1332-9A\>G (exon 12) and c.10086+5G\>C (exon 69), showed transcripts presenting skipping of the mutated exon and other neighbouring exons. These findings suggest a kind of priming effect in some exons, as previously observed in other genes [@pone.0059916-Baralle1], and reinforce the idea that the overall pre-mRNA architecture might be involved in the splicing process [@pone.0059916-Buratti1].

![Relative ESE density versus relative 3′ ss strength in in-frame exons presenting nonsense and frameshift mutations.\
On the y axis: difference between exon PESE density and mean density of all *DMD* exons. On the x axis: difference between 3′ ss MaxEnt score and next distal natural 3′ ss score. Non-filled circles represent exons with DMD/IMD-associated mutations, while grey-filled circles represent exons with BMD-associated mutations. Black bordered circles indicate exons without PESE disruptions. Blue bordered circles indicate exons with PESE disruption. Exon numbers are indicated beside circles.](pone.0059916.g004){#pone-0059916-g004}

We observed that most splice site mutations induce variable levels of multiple alternatively spliced transcripts. Probably for this reason, splice site mutations are more frequent in BMD than in DMD. The splicing pathway differs substantially from one mutation to another, with main outcomes consisting in exon-skipping or activation of alternative sites. Intron retention was found only in one case and involved the smallest *DMD* intron (107 bp), in line with previous findings [@pone.0059916-Galante1]. Several mutations induce more than one pathway at the same time. For this reason, predicting how these mutations will affect splicing patterns without mRNA studies is challenging. Algorithms such as HSF and MaxEnt are useful tools to predict abrogation or reduction of splice site function, creation of new sites and presence of cryptic sites. Changes located in non-canonical AG or GT nucleotides, slightly reducing the site strength are expected to induce significant amounts of normally spliced transcripts. However, this can not be generalized to all mutations. While mutations c.3603+2dupT and c.9563+5G\>C induced significant amounts of normally spliced transcripts, c.3432+3A\>T and c.10086+5G\>C induced mainly aberrant transcripts ([Table 2](#pone-0059916-t002){ref-type="table"}). These findings and the variety of observed splicing outcomes indicate that factors other than splice sites influence the final pattern. Multiple factors have been suggested to determine the splicing pathway, including the sequence context of the affected splice site, exon and intron length, RNA secondary structures, and conservation of the reading frame [@pone.0059916-Buratti1], [@pone.0059916-Zhang3], [@pone.0059916-Roca1]. The abundance of cryptic splice sites has been suggested as a main factor determining whether a mutation induces exon-skipping or cryptic splice site activation [@pone.0059916-Krawczak1]. Confirming a previous work [@pone.0059916-Habara1], our data indicate that the availability of cryptic splice site does not determine the main splicing pathway, since numerous potential sites are found in most analyzed exons according to HSF and MaxEnt predictions. Habara et al. proposed that in +1G\>A mutations a strong exon recognition, resulting from the combination of a high 3′ ss score and a long exon length, is necessary for cryptic site activation [@pone.0059916-Habara1]. Our data indicate that the splicing pathway in 5′ ss mutations is determined by the interplay between the relative strength of 3′ ss and the density of ESE elements ([Figure 3](#pone-0059916-g003){ref-type="fig"}). Cryptic site activation occurs in those exons that present a strong 3′ ss compared with the next distal exon, while weak 3′ ss lead to exon-skipping. However, two exceptions are found in our subset of exons. Exon 26 presenting a weak 3′ ss showed cryptic site activation, while exon 69 presenting a moderately strong 3′ ss showed exon-skipping ([Figure 3C](#pone-0059916-g003){ref-type="fig"}). We hypothesize that a high density of ESE motifs may compensate a weak 3′ ss, leading to activation of alternative splice sites. In the other hand, a low ESE density in a moderately strong 3′ ss context may contribute to exon-skipping.

Precise identification of *DMD* mutations and their consequences on mRNA and protein expression is essential to provide accurate genetic counseling in dystrophinopathy families and to include patients in mutation suppression therapies. Our results support and extend previous findings showing that 3′ ss strength and density of regulatory elements are determinant factors of the splicing pathway in mutations affecting splicing signals. However, other factors such as the genomic context may also play a relevant role, suggesting a more complex model. Understanding the splicing code and developmenting computational splicing models will be of great value to predict pathological effects of DNA variants in molecular diagnosis of dystrophinopathy and other diseases, and to design more efficient molecules for splicing modulation therapies.
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**Nonsense and frameshift mutations located in in-frame exons were analyzed using different matrices to predict creation or disruption of splicing regulatory elements.** For ESE matrices, 1 represents disruption of at least one ESE motif while 0 represents no disruption; for ESS matrices, 1 represents creation of an ESS motif while 0 represents no creation.
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Click here for additional data file.

###### 

**Primer pairs used to perform semi-quantitative QF-PCR in muscle cDNA are listed.** Primer name indicates its exonic location in the cDNA. For each amplicon, length of normal transcript and analyzed mutations are indicated.

(DOC)

###### 

Click here for additional data file.
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